
Benzinga Pro data, Fulcrum Therapeutics (NASDAQ:FULC) reported Q4 sales of $5.06 million. Earnings fell to a loss of $23.48 million, resulting in a 13.36% decrease from last quarter. Fulcrum Therapeutics collected $4.93 million in revenue during Q3, but reported earnings showed a $20.72 million loss.